US FDA approves Merck's pill combo to treat HIV infection

The FDA approved Merck's once-daily oral HIV regimen Idvynso, a two-drug combination of doravirine and islatravir, for replacing current antiretroviral therapy in some adults. Merck said late-stage studies with more than 1,000 patients met the main endpoint of significantly suppressing HIV-1 replication, and the company is positioning the drug as part of a longer-term HIV franchise build. RBC Capital Markets expects limited near-term commercial impact, with upside tied to future approval in treatment-naive patients.

Analysis

This approval matters less as an immediate revenue event and more as a proof point that Merck can keep a post-key-patent-growth narrative alive in infectious disease. The market will likely underwrite only modest near-term contribution because switch therapy in HIV is a relatively mature, sticky category where formulary inertia and physician conservatism slow rapid share changes. The real optionality is whether this becomes a platform for regimen simplification that later expands into treatment-naïve patients, which would meaningfully widen the addressable base and shift the asset from niche maintenance therapy to a branded franchise.

Competitive dynamics are more interesting than the headline suggests. Any incremental share taken from the current standard-of-care oral regimens is likely to come disproportionately from lower-friction switching rather than broad new patient capture, which means the first-order loser is not necessarily the largest incumbent brand but rather the weakest payer-positioned alternatives with less durable clinical differentiation. A cleaner oral option also increases the value of next-wave convenience features such as weekly dosing and long-acting formulations; if Merck can extend dosing interval without losing efficacy, it forces rivals to defend on adherence rather than pure virologic suppression.

The key risk is execution, not regulation: safety, durability, and resistance data will matter far more over the next 6-18 months than this approval alone. If clinicians see any signal that the experimental component is more fragile than expected, uptake could stall quickly and the asset could be relegated to a small switch population. Conversely, if management can show low discontinuation and payer acceptance, this becomes a slow-burning but credible contributor to a more diversified growth profile rather than a one-off label expansion.

The contrarian take is that consensus may still be too dismissive of the strategic value here. In HIV, small improvements in convenience can produce outsized lifetime value because persistence is high and switching costs are mostly clinical rather than behavioral; that makes even a modest share gain more durable than the market typically prices in for mature pharma launches.

Key Decisions for Investors

• Long MRK on a 3-6 month horizon; use any post-news consolidation as entry. Upside is not the initial launch print but optionality around broader label expansion and a deeper HIV franchise, with downside limited unless follow-on data disappoints.
• Pair: long MRK / short a basket of HIV-exposed large-cap pharma peers with weaker pipeline catalysts over the next 6-12 months. The thesis is relative multiple support for MRK if the market starts to assign franchise durability to Idvynso.
• For event-driven accounts, buy MRK call spreads 6-12 months out rather than outright stock. The launch is likely to be gradual, so convexity is better priced via options than through directional equity exposure.
• Monitor next catalyst window for treatment-naïve data; if positive, add to MRK aggressively because that is the inflection point where commercial expectations can re-rate meaningfully.
• Avoid chasing any immediate move in MRK tied to the approval itself; the first-order revenue impact is likely too small to justify paying up before real-world adoption data emerges.